Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

被引：0
|
作者：
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Gustave Roussy, Villejuif, France
[3] Bradford Hill Clin Res Ctr, Santiago, Chile
[4] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Univ Bari Aldo Moro, Bari, Italy
[9] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[11] Oncoclin Grp, Porto Alegre, Brazil
[12] Fdn Richardet Longo, Inst Oncol Cordoba, Cordoba, Argentina
[13] Westmead Hosp, Westmead, NSW, Australia
[14] Macquarie Univ, Westmead, NSW, Australia
[15] Westmead Hosp, Sydney, NSW, Australia
[16] Macquarie Univ, Sydney, NSW, Australia
[17] Univ Colorado, Sch Med, Aurora, CO USA
[18] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[19] Eva Mayr Stihl Canc Ctr, Klinikum Stuttgart, Stuttgart, Germany
[20] Exelixis Inc, Alameda, CA USA
[21] Bristol Myers Squibb, Princeton, NJ USA
[22] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[23] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [32] Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
    Gruenwald, Viktor
    Choueiri, Toni K.
    Rini, Brian I.
    Powles, Thomas
    George, Saby
    Grimm, Marc-Oliver
    Mchenry, M. Brent
    Maurer, Matthew
    Motzer, Robert J.
    Hammers, Hans J.
    Tannir, Nizar M.
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 74 - 75
  • [33] Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma (OCT, 10.1080/14796694.2024.2415786, 2024)
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Choueiri, Toni K.
    Apolo, Andrea B.
    FUTURE ONCOLOGY, 2024,
  • [34] GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB PLUS IPILIMUMAB (N plus I) VERSUS NIVOLUMAB PLUS CABOZANTINIB (N plus C) AND PEMBROLIZUMAB PLUS AXITINIB (P plus A) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    McGregor, B.
    Geynisman, D.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Sendhil, S.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    VALUE IN HEALTH, 2021, 24 : S28 - S29
  • [35] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Motzer, R. J.
    Powles, T.
    Burotto, M.
    LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319
  • [36] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Vergote, I
    Gonzalez-Martin, A.
    Lorusso, D.
    LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
  • [37] Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.
    Cella, David
    Motzer, Robert J.
    Blum, Steven I.
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel
    Zhang, Joshua
    Simsek, Burcin
    Ivanescu, Cristina
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Atkins, Michael B.
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian I.
    Jiang, Ruiyun
    Desilva, Heshani
    Lee, Chung-Wei
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363
  • [39] Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N plus C) versus sunitinib (SUN) in treatment-naive, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.
    Cella, David
    Motzer, Robert J.
    May, Jessica
    Wallace, Joel
    Marteau, Florence
    Kwon, Youngmin
    Rusibamayila, Nifasha
    Botteman, Marc
    Ejzykowicz, Flavia
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N plus C) vs pembrolizumab plus axitinib (P plus A) in previously untreated advanced renal cell carcinoma (aRCC)
    Porta, C. G.
    Motzer, R.
    Ejzykowicz, F.
    Blum, S. I.
    Hamilton, M.
    May, J. R.
    Huo, S.
    Kral, P.
    Ivanescu, C.
    Choueiri, T. K.
    Cella, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S692 - S693
12345